Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNFRSF1A | P19438 | 4/20 | 0.76 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.66 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 1/20 | 0.60 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.60 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16246460 | 1.00 | TNFRSF1A (0.76) | TNFRSF1ASMPD1HDAC1HDAC8HDAC6 | |
| SCHEMBL25301594 | 0.91 | APP (0.70) | TNFRSF1AABCG2PDE4APDE4BPDE4C | |
| SCHEMBL31420052 | 0.88 | NPC1 (0.70) | ABCG2MAOBPDE4APDE4BPDE4C | |
| SCHEMBL21643434 | 0.87 | ABCG2 (0.63) | TNFRSF1AABCG2PDE4APDE4BPDE4C | |
| SCHEMBL21643440 | 0.87 | ABCG2 (0.63) | TNFRSF1AABCG2PDE4APDE4BPDE4C | |
| 3',4'-Dimethoxychalcone SCHEMBL12485314 | 0.87 | TNFRSF1A (1.00) | TNFRSF1AABCG2ABCB1MAOBMEN1 | |
| 3',4'-Dimethoxychalcone SCHEMBL12485318 | 0.87 | TNFRSF1A (1.00) | TNFRSF1AABCG2ABCB1MAOBMEN1 | |
| SCHEMBL8062149 | 0.85 | PTPN1 (0.61) | TNFRSF1ASMPD1HDAC1HDAC8HDAC6 | |
| SCHEMBL21643517 | 0.85 | PDE4A (0.67) | TNFRSF1AABCG2PDE4APDE4BPDE4C | |
| SCHEMBL29803332 | 0.85 | PDE4A (0.67) | TNFRSF1AABCG2PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2994460-B1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | UNIV INDIANA RES & TECH CORP (US) | 2024-12-04 | — | — | EP | disclosed |
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2018-06-28 | — | — | US | disclosed |
| EP-2994460-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | Indiana University Research and Technology Corporation (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | GACHON UNIVERSITY OF INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2016-03-03 | — | — | US | disclosed |
| WO-2014182695-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738024-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | TNFRSF1A 598/4885SMPD1 649/4885HDAC1 3186/4885 |
| US-20180177758-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | TNFRSF1A 598/4885SMPD1 649/4885HDAC1 3186/4885 |
| US-20160060241-A1 | COMPOUNDS FOR TREATMENT OF ANGIOGENESIS-MEDIATED DISEASES | KDR, TEK, VEGFA | TNFRSF1A 598/4885SMPD1 649/4885HDAC1 3186/4885 |
| US-10238627-B2 | Compounds for treatment of angiogenesis-mediated diseases | KDR, TEK, VEGFA | TNFRSF1A 598/4885SMPD1 649/4885HDAC1 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.